Key Takeaways KMTS announced a collaboration with Biobeat, including an exclusive license and a $5M Series B investment.KMTS integrates FDA-cleared cuffless blood pressure monitoring into the ASSURE WCD for at-home recovery.Per Kestra, ACE-PAS data reflects 72% hypertensive patients, highlighting BP challenges post-cardiac events.Kestra Medical Technologies, Ltd.(KMTS) announced a collaboration with Biobeat Technologies, Ltd. to improve patient monitoring and diagnosis insights for people who rely on the AS ...